Startup profile · funding coverage
Assurex Health
Pharmacogenomic testing (GeneSight) to guide mental health medication decisions — acquired by Myriad Genetics.
Stage
acquired
Status
acquired
Coverage
full
Overview
Assurex Health developed GeneSight psychotropic pharmacogenomic tests. Founded 2006 with IP licensed from Cincinnati Children’s and Mayo Clinic. August 2016: Myriad Genetics announced acquisition for $225M upfront with up to $185M milestones; HQ remained in Mason, Ohio. Early seed support included CincyTech.
Why Assurex Health is interesting
Cincinnati-metro (Mason, OH) precision-medicine exit: Myriad deal $225M upfront (+$185M milestones) in 2016; early CincyTech support; HQ kept in Mason.
Product & use cases
Combinatorial pharmacogenomic reports (GeneSight) to inform psychotropic medication selection.
- Psychiatry medication selection support
- Health-system precision medicine programs
Key facts
- Acquired by Myriad Genetics (2016): $225M upfront + up to $185M milestones
- HQ remained Mason, Ohio post-deal
- Early investor/support: CincyTech
- Product: GeneSight psychotropic genetic testing
Fundraising history
Acquisition
2016-08 $225M upfront (+$185M milestones)- Myriad Genetics (lead)
Source: https://genesight.com/news-and-press/assurex-health-to-be-acquired-by-myriad-genetics-2/
Investors in our directory
Funds linked from Assurex Health's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Clinical utility studies + Medicare LCD history in psychotropic PGx category.
-
Genomind direct
Psychiatric pharmacogenomics.
-
Tempus / other PGx adjacent
Broader precision medicine.
Industries
FAQs about Assurex Health
Practical answers founders, operators, and investors typically search for.
Last updated: 2026-07-26